Your browser doesn't support javascript.
loading
The combined signatures of the tumour microenvironment and nucleotide metabolism-related genes provide a prognostic and therapeutic biomarker for gastric cancer.
Liu, Jifeng; Zhong, Lei; Deng, Dawei; Zhang, Yunshu; Yuan, Qihang; Shang, Dong.
Afiliación
  • Liu J; Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
  • Zhong L; Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
  • Deng D; Department of Hepato-Biliary-Pancreas, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
  • Zhang Y; Department of Traditional Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. zys1986062186@163.com.
  • Yuan Q; Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. qihangdy@163.com.
  • Shang D; Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. shangdong@dmu.edu.cn.
Sci Rep ; 13(1): 6622, 2023 04 24.
Article en En | MEDLINE | ID: mdl-37095256
The tumour microenvironment (TME) is vital to tumour development and influences the immunotherapy response. Abnormal nucleotide metabolism (NM) not only promotes tumour cell proliferation but also inhibits immune responses in the TME. Therefore, this study aimed to determine whether the combined signatures of NM and the TME could better predict the prognosis and treatment response in gastric cancer (GC). 97 NM-related genes and 22 TME cells were evaluated in TCGA-STAD samples, and predictive NM and TME characteristics were determined. Subsequent correlation analysis and single-cell data analysis illustrated a link between NM scores and TME cells. Thereafter, NM and TME characteristics were combined to construct an NM-TME classifier. Patients in the NMlow/TMEhigh group exhibited better clinical outcomes and treatment responses, which could be attributed to the differences in immune cell infiltration, immune checkpoint genes, tumour somatic mutations, immunophenoscore, immunotherapy response rate and proteomap. Additionally, the NMhigh/TMElow group benefited more from Imatinib, Midostaurin and Linsitinib, while patients in the NMlow/TMEhigh group benefited more from Paclitaxel, Methotrexate and Camptothecin. Finally, a highly reliable nomogram was developed. In conclusion, the NM-TME classifier demonstrated a pretreatment predictive value for prognosis and therapeutic responses, which may offer novel strategies for strategizing patients with optimal therapies.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido